FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2900629850> ?p ?o ?g. }

• W2900629850 endingPage "3187" @default.
• W2900629850 startingPage "3187" @default.
• W2900629850 abstract "Abstract 【Background】The use of novel agents with different mechanisms of action has resulted in high complete response (CR) rates and improved the survival of patients with multiple myeloma (MM). Obtaining minimal residual disease (MRD) negativity following treatment is an important determinant for longer survival in patients with MM. The EuroFlow MM-MRD panel (EuroFlow panel) using the Infinicyt software (Cytognos, Salamanca, Spain) is a two-tube six-color antibody panel. By the addition of two drop-in antibodies (CD138, CD27; vendor of user's choice) into both tubes, an eight-color configuration, which has been validated by the EuroFlow consortium is obtained. The DuraClone RE PC kit (DuraClone panel) is a recently developed one-tube eight-color dry antibody panel using the Kaluza software (Beckman Coulter, Miami, USA) for manual identification of abnormal plasma cells (PCs) to detect MRD in MM. Although both methods are available, a comparison between them has yet to be performed. This study aimed to compare the EuroFlow panel and the DuraClone panel analysis of residual abnormal plasma cells by eight-color flow cytometry. 【Methods】Patients with International Myeloma Working Group defined symptomatic MM treated at Kanazawa University Hospital and Kameda Medical Center in Japan from January 2017 to July 2018 were included. Bone marrow samples were obtained as part of routine clinical practice for evaluating treatment response when appropriate. Bone marrow aspirates (4 mL; first pull of bone marrow aspiration) anti-coagulated with ethylenediamine tetraacetic acid were evenly split (2 mL each) for the EuroFlow panel and the DuraClone panel. PC quantification by the EuroFlow panel was performed at Kanazawa University Hospital and the DuraClone panel was performed at Kameda Medical Center. The monoclonal antibodies used in the EuroFlow and the DuraClone panels are detailed in Table 1. Identification of neoplastic PCs required ≥ 20 cells. Sample processing and measurement of PCs were performed within 48 hours of collection. The correlation of total leukocyte acquisition, total plasma cells and MRD were analyzed for both methods. Qualitative comparison of MRD negativity was also performed. Spearman's correlation coefficient was used for evaluating the correlation of paired data. The Bland-Altman plot was used for detection of fixed bias and proportional bias. 【Results】A total of 79 samples were analyzed. We first assessed the number of total leukocytes using the EuroFlow panel and the DuraClone panel. The median number of total leukocytes acquired with the EuroFlow panel was significantly higher than with the DuraClone panel (median: 8,505,172 cells, interquartile range [IQR]: 6,164,094 - 9,105,097 cells and median: 2,858,026 cells, IQR: 1,466,004 - 4,284,926 cells, respectively; p < 0.01), but the percentage of total plasma cells showed good concordance between both methods (regression coefficient = 0.91, p < 0.01). The median percentage of abnormal plasma cells was 0.0035% (IQR: 0.0005 - 0.05) and 0.0046% (IQR: 0.0005 - 0.05) using the EuroFlow panel and the DuraClone panel, respectively. Figure 1A shows scatter plots comparing the percentage of abnormal cells analyzed using the EuroFlow panel and the DuraClone panel. Both methods showed a high degree of concordance (regression coefficient = 0.90, p < 0.01). Bland-Altman plots also showed good agreement between both methods. There was no statistically significant fixed bias with a mean difference of 10% (95% confidence interval [CI]: -12~14%). In addition, no significant proportional bias was detected between the two methods (regression coefficient: -0.01, p = 0.85; Figure 1B). Qualitative analysis of MRD negativity also showed substantial agreement between the two methods (kappa = 0.7); 11 of 79 (13.9 %) samples showed discrepancy for determination of MRD negativity (< 1 × 10-5). Nine of these samples were MRD negative by the EuroFlow panel, but MRD positive by the DuraClone panel, and two samples were MRD positive by the EuroFlow panel, but MRD negative by the DuraClone panel. However, all discrepancies occurred near the limit of detection of both methods (1.0 × 10-5). 【Conclusion】Our findings indicate that the DuraClone panel has good overall concordance with the EuroFlow panel for the detection of abnormal PCs in MM samples. The one-tube DuraClone panel enables to reduce processing time and test cost compared with the two-tube EuroFlow panel. Disclosures Takamatsu: Celgene: Honoraria, Research Funding; Janssen: Honoraria; Bristol-Myers Squibb: Research Funding; Ono: Research Funding. Nakao:Alexion Pharmaceuticals, Inc.: Consultancy, Honoraria; Kyowa Hakko Kirin Co., Ltd.: Honoraria; Novartis: Honoraria." @default.
• W2900629850 created "2018-11-29" @default.
• W2900629850 creator A5008833770 @default.
• W2900629850 creator A5020298977 @default.
• W2900629850 creator A5025340212 @default.
• W2900629850 creator A5028349481 @default.
• W2900629850 creator A5034343487 @default.
• W2900629850 creator A5077009374 @default.
• W2900629850 date "2018-11-29" @default.
• W2900629850 modified "2023-09-28" @default.
• W2900629850 title "Quantification of Residual Bone Marrow Plasma Cells By Eight-Color Flow Cytometry in Patients with Multiple Myeloma: Comparison between the Dura Clone RE PC Panel (Beckman Coulter) and the Euro Flow MM-MRD Panel (Cytognos)" @default.
• W2900629850 doi "https://doi.org/10.1182/blood-2018-99-116108" @default.
• W2900629850 hasPublicationYear "2018" @default.
• W2900629850 type Work @default.
• W2900629850 sameAs 2900629850 @default.
• W2900629850 citedByCount "0" @default.
• W2900629850 crossrefType "journal-article" @default.
• W2900629850 hasAuthorship W2900629850A5008833770 @default.
• W2900629850 hasAuthorship W2900629850A5020298977 @default.
• W2900629850 hasAuthorship W2900629850A5025340212 @default.
• W2900629850 hasAuthorship W2900629850A5028349481 @default.
• W2900629850 hasAuthorship W2900629850A5034343487 @default.
• W2900629850 hasAuthorship W2900629850A5077009374 @default.
• W2900629850 hasConcept C126322002 @default.
• W2900629850 hasConcept C142724271 @default.
• W2900629850 hasConcept C203014093 @default.
• W2900629850 hasConcept C2776364478 @default.
• W2900629850 hasConcept C2779823535 @default.
• W2900629850 hasConcept C2780007613 @default.
• W2900629850 hasConcept C2989005 @default.
• W2900629850 hasConcept C553184892 @default.
• W2900629850 hasConcept C71924100 @default.
• W2900629850 hasConceptScore W2900629850C126322002 @default.
• W2900629850 hasConceptScore W2900629850C142724271 @default.
• W2900629850 hasConceptScore W2900629850C203014093 @default.
• W2900629850 hasConceptScore W2900629850C2776364478 @default.
• W2900629850 hasConceptScore W2900629850C2779823535 @default.
• W2900629850 hasConceptScore W2900629850C2780007613 @default.
• W2900629850 hasConceptScore W2900629850C2989005 @default.
• W2900629850 hasConceptScore W2900629850C553184892 @default.
• W2900629850 hasConceptScore W2900629850C71924100 @default.
• W2900629850 hasIssue "Supplement 1" @default.
• W2900629850 hasLocation W29006298501 @default.
• W2900629850 hasOpenAccess W2900629850 @default.
• W2900629850 hasPrimaryLocation W29006298501 @default.
• W2900629850 hasRelatedWork W1882523775 @default.
• W2900629850 hasRelatedWork W2005843898 @default.
• W2900629850 hasRelatedWork W2049272687 @default.
• W2900629850 hasRelatedWork W2078954288 @default.
• W2900629850 hasRelatedWork W2092406936 @default.
• W2900629850 hasRelatedWork W2384925166 @default.
• W2900629850 hasRelatedWork W2733711466 @default.
• W2900629850 hasRelatedWork W2981308154 @default.
• W2900629850 hasRelatedWork W3030951506 @default.
• W2900629850 hasRelatedWork W4312732654 @default.
• W2900629850 hasVolume "132" @default.
• W2900629850 isParatext "false" @default.
• W2900629850 isRetracted "false" @default.
• W2900629850 magId "2900629850" @default.
• W2900629850 workType "article" @default.